Jiyang YU
Assistant Member, St. Jude Children's Research Hospital, USA

Dr. Yu received his bachelor degree in Computer Science from Zhejiang University, China 2006 and his PhD in Biomedical Informatics from Columbia University 2012 under supervision of Dr. Andrea Califano. After his PhD, Dr. Yu joined Pfizer Oncology as a Senior Scientist in the Department of Precision Medicine, where he led the computational functional genomics group for target identification. In November 2016, Dr. Yu started his own lab in the Department of Computational Biology at St. Jude.


Dr. Yu's research has been focused on translational and precision medicine using systems biology and functional genomics approaches. He has authored over 15 peer-reviewed publications in top journals including Cancer Cell, Cancer Research, Bioinformatics, Leukemia, Blood, Genes & Development, etc.


Two of Dr. Yu's discoveries have successfully launched two clinical trials for breast cancer at Columbia University and Mount Sinai School of Medicine and one network-based biomarker being patented and tested in one of the trials. Dr. Yu has developed sophisticated analytical algorithms, e.g. ScreenBEAM for high-throughput RNAi and CRISPR screens.


In his current lab at St. Jude, Dr. Yu is developing novel computational and systems biology approaches and functional genomic CRISPR platforms to i) identify "hidden" regulatory, signaling and immunologic modulators/modules that drive tumorigenesis, tumor immunity and drug resistance, ii) develop network-based companion biomarkers to predict patient response and to repurpose existing drugs, and iii) systematically predict and evaluate combination therapies for cancer, particularly with immunotherapy, with a focus on but not limited to, pediatric brain tumors, high-risk neuroblastoma and relapsed leukemia.